GPhA applauds FDA's action to address shortage of Doxil, methotrexate

WASHINGTON — The Food and Drug Administration's action to address the ongoing shortage of certain cancer drugs has garnered praise from a group representing the manufacturers and distributors of generic pharmaceuticals.

The Generic Pharmaceutical Association said it applauded the FDA's action to address the shortage of cancer drugs Doxil (doxorubicin hydrochloride liposome injection) and preservative-free methotrexate. GPhA also added that generic drug manufacturers are tirelessly working with regulators to provide needed supplies of the critical medicines.

“As FDA commissioner Margaret Hamburg said this morning, patients and families waiting for these drugs will soon be able to get the medication they need thanks to the collaborative work of FDA, industry, and other stakeholders,” GPhA president and CEO Ralph Neas said. “GPhA is spearheading the development of the Accelerated Recovery Initiative — an unprecedented multi-stakeholder undertaking that would work with entities across the supply chain to enhance communication and strengthen our collective ability to prepare for potential shortages and make sure patients do not face situations where their medicines are not available.”

Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.